Inhibikase Therapeutics, Inc. · NASDAQ:IKT

Inhibikase Therapeutics — Investor Presentation (September 2026)

32 slides from Inhibikase Therapeutics's investor presentation, September 2026

  1. Slide 1: Corporate Overview

    Corporate Overview September 2026

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains information that may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Inhibikase Therapeutics, Inc. (the “Company” or “we”) intends for the forward-looking statements to be covered by

  3. Slide 3: Inhibikase & IKT-001: Pulmonary Arterial Hypertension (PAH)

    Inhibikase & IKT-001: Pulmonary Arterial Hypertension (PAH) ~30% 45 meters 1st Late Stage 5-year mortality1 placebo-adjusted 6MWD gain3 oral once-daily anti-proliferative Phase 3 program currently enrolling HIGH UNMET NEED STRONG EFFICACY INFORMED DESIGN POSITIONED TO EXECUTE • PAH is rare, progress

  4. Slide 4: Experienced Leadership with Deep Expertise in PAH

    Experienced Leadership with Deep Expertise in PAH MARK IWICKI CHRIS CABELL, MD MHS FACC DAVID McINTYRE BEC CPA LLB MBA Chief Executive Officer Head of R&D, Chief Medical Officer Chief Financial Officer JOHN ADAMS, PHD TIM PIGOT JEFF KAGY Chief Scientific Officer Chief Commercial Officer Chief Human

  5. Slide 5: PAH is Progressive Disease Driven by Uncontrolled Cell Proliferation

    PAH is Progressive Disease Driven by Uncontrolled Cell Proliferation Proliferation of vascular cells drive vascular remodeling, raising pulmonary artery pressure and leading to progressive right ventricular heart failure and ultimately death 5 PASMCs = Pulmonary artery smooth muscle cells; Vascular

  6. Slide 6: PAH: Orphan Disease with ~30% 5-Year Mortality Despite Aggressive Treatment

    PAH: Orphan Disease with ~30% 5-Year Mortality Despite Aggressive Treatment High Unmet Medical Need ~50,000 52 years Progressive and Life Threatening People with PAH in the US(1) Average age at diagnosis(2) • ~30% 5-year mortality(3) despite high diagnosis rate and specialist directed treatment with

  7. Slide 7: Patient and Treatment Journey in PAH

    Patient and Treatment Journey in PAH Progressive Pulmonary Vasculopathy Driving Right Heart Failure And Death Low Risk Intermediate Risk High Risk 3% Risk Of 1 Year Mortality 4-19% Risk Of 1 Year Mortality >20% Risk Of 1 Year Mortality WHO Functional Class 1&2 WHO Functional Class 3 WHO Functional C

  8. Slide 8: Antiproliferatives Expected to Rapidly Grow the PAH Market

    Antiproliferatives Expected to Rapidly Grow the PAH Market IKT-001 has the potential to be the First Once-Daily Oral Antiproliferative for PAH Vasodilators 2025 Prostacyclin Pathway ($3.94B) $8.3 Billion* Antiproliferative Segment Could Reach $8 Billion by 2034** Epoprostenol, Treprostinil, Iloprost

  9. Slide 9: IKT-001

    IKT-001

  10. Slide 10: IKT-001's Path to Best-in-Class in PAH

    IKT-001’s Path to Best-in-Class in PAH IKT-001 On Track to be the First Oral Antiproliferative with a Strong Potential Profile 1 Class-Leading Efficacy* 2 Improved Safety Profile* 3 Clinical Benefits* IKT-001 imatinib Oral Intact in GI: enzymatic cleavage in blood 45 Novel Once-daily Meters* Prodrug

  11. Slide 11: Imatinib Mechanism of Action Targets the Underlying Cause of PAH

    Imatinib Mechanism of Action Targets the Underlying Cause of PAH • Overactive kinases implicated in aberrant cell proliferation and migration in the pulmonary vasculature • Imatinib inhibits the tyrosine kinase activity of PDGFRs and c-Kit, blocking cell signaling that drives vascular remodeling • A

  12. Slide 12: Imatinib Demonstrated Reversal of PAH in Standard Animal Model

    Imatinib Demonstrated Reversal of PAH in Standard Animal Model1 Reversal of pulmonary Reversal of increased right Improved survival vascular remodeling ventricular pressure Day 0 MCT d42 MCT d42/+imatinib imatinib imatinib Imatinib reverses pulmonary vascular remodeling, right ventricular pressure/r

  13. Slide 13: IKT-001 Retains Imatinib Efficacy & PAH Reversal Profile in Pre-Clinical Model

    IKT-001 Retains Imatinib Efficacy & PAH Reversal Profile in Pre-Clinical Model Lung Histology Mean Pulmonary Artery Pressure (mPAP) Background: Imatinib has previously been shown to reverse PAH in the Sugen-hypoxia Rat Model(1) Su/Hypoxia/Veh d43 Like imatinib, chronic treatment with IKT-001 reverse

  14. Slide 14: IKT-001 Dramatically Reduces GI Imatinib Exposure to Drive Tolerability

    IKT-001 Dramatically Reduces GI Imatinib Exposure to Drive Tolerability* IKT-001 is Stable in the Gut and has Rapid Bioconversion in the Blood Blood Pre-absorption: IKT-001 Is Stable In Gut* imatinib • GI tract protected from direct imatinib exposure IKT-001 IKT-001 • ~20x less inhibition of tyrosin

  15. Slide 15: IKT-001 Has Reduced Gut Motility Impairment vs Imatinib

    IKT-001 Has Reduced Gut Motility Impairment vs Imatinib IKT-001 remains intact in the stomach and intestine and is 18X less potent at c-Kit than imatinib1 IKT-001 has No Effect on Gastric Emptying Imatinib & 0.4 Morphine Delay * Gastric Gastric Content (g) * 0.3 IKT-001 Not Statistically Emptying Di

  16. Slide 16: Additive Efficacy Via Combination of IKT-001 + Activin Signaling Inhibitor

    Additive Efficacy Via Combination of IKT-001 + Activin SignaIing Inhibitor Activin Signaling Inhibitor (RAP – sotatercept surrogate) Plus IKT-001 in PAH Sugen-Hypoxia Model Mean Pulmonary Artery Pressure mPAP 80  Statistically significant additive improvements in 60 -24% -27% PAH hemodynamics mPAP

  17. Slide 17: Clinical Rationale

    Clinical Rationale

  18. Slide 18: SAD Study in Healthy Volunteers Establishes Bioequivalence

    SAD Study in Healthy Volunteers Establishes Bioequivalence Bioequivalent IKT-001 Dose Imatinib Dose 300 mg QD 230 mg QD 400 mg QD 306 mg QD 500 mg QD 383 mg QD 18 IKT Data on File; SAD: Single ascending dose study CONFIDENTIAL

  19. Slide 19: IMPRES – Imatinib Phase 3 Study

    IMPRES – Imatinib Phase 3 Study Randomized controlled trial to assess the efficacy and safety of imatinib once daily (n=202) Imatinib 200mg 400mg with ability to down titrate to 200mg if unable to tolerate 400mg (n=103) Placebo (n=99) Weeks 0 4 8 12 16 20 24 Short 2 Week Titration IKT’s Phase 3 IMPR

  20. Slide 20: IMPRES: Statistically Significant Improvements in Function & Hemodynamics

    IMPRES: Statistically Significant Improvements in Function & Hemodynamics Placebo-adjusted 32-meter improvement in 6MWD and 32% reduction in PVR at week 24 Majority of Subjects on 200 mg of Imatinib at End of Study Change in Change in Pulmonary Change in 6-Minute Walk Distance Vascular Resistance Ca

  21. Slide 21: Imatinib Showed Comparable Efficacy to Sotatercept

    Imatinib Showed Comparable Efficacy to Sotatercept Majority of Sotatercept Subjects at Highest Dose While Majority of Imatinib Subjects at Lowest Dose Sotatercept Phase 3 STELLAR1 Imatinib Phase 3 IMPRES2 6MWD 10 Endpoint: Median Treatment Difference = 33.4m 10 Endpoint: Mean Treatment Difference =

  22. Slide 22: IMPRES: Patients Able To Sustain 400mg Dose Showed Greater Improvements

    IMPRES: Patients Able To Sustain 400mg Dose Showed Greater Improvements Placebo-adjusted 6MWD Improvement of 45m in Patients at 400mg for >50% of Treatment Changes in 6MWD at Week 24 Changes in PVR at Week 24 400mg for > 50% of 400mg for < 50% of 60 treatment treatment Placebo 50 0 50 -50 -10 45 met

  23. Slide 23: Targeting An Improved AE Profile To Help Patients Maintain Higher Doses

    Targeting An Improved AE Profile To Help Patients Maintain Higher Doses Imatinib Phase 3 IMPRES1 Trial Imatinib Placebo IKT-001 and IMPROVE-PAH Study Design n=103 (%) n=98 (%) Combine to Mitigate IMPRES AE Challenges Adverse Events 100 (97) 94 (96) Nausea 57 (55) 23 (24) • IKT-001 is designed to hav

  24. Slide 24: Recent Study of Imatinib Supports Findings from IMPRES

    Recent Study* of Imatinib Supports Findings from IMPRES Doses between 200mg – 400mg delivered meaningful efficacy response Dose Dependent Improvement in Primary Endpoint 2025 Publication Using Imatinib in PAH PAH patients (13/17) with implanted devices to assess continuous cardiac function Comparabl

  25. Slide 25: Rapid & Sustained Hemodynamic Effect With Evidence of Disease Modification

    Rapid & Sustained Hemodynamic Effect With Evidence of Disease Modification Imatinib Delivered a 24% Reduction in Total Pulmonary Resistance (TPR) Early & Continued Improvement Slow return to BL 1 Early Improvement in TPR 3 2 Slow return to baseline 24% Reduction suggests disease in TPR modification

  26. Slide 26: IKT's Clinical Program

    IKT’s Clinical Program

  27. Slide 27: IMPROVE-PAH Phase 3 Study of IKT-001

    Phase 3 Enrollment Ongoing IMPROVE-PAH Phase 3 Study of IKT-001 Enrollment Continues Phase 3 – Part A Uninterrupted Phase 3 – Part B Double Blind Treatment (n=140) Double Blind Treatment (n=346) n=70 300 400 500 Max Tolerated Dose QD n=173 300 400 500 Max Tolerated Dose QD Interim Primary Analysis 1

  28. Slide 28: Power of Titration & Improved Study Design in IMPROVE-PAH

    Power of Titration & Improved Study Design in IMPROVE-PAH 1 Gradual titration to max. tolerated dose to retain IMPRES efficacy 2 Improved administration to ↓ discontinuations Gradual Titration P3: IMPRES Rapid 2-week escalation ✓ Slower pace to Cmax steady-state allows patient to 200 400 adapt to IK

  29. Slide 29: Why IMPROVE-PAH Phase 3 Has Higher Probability of Success

    Why IMPROVE-PAH Phase 3 Has Higher Probability of Success Modern Phase 3 Design + IKT-001’s Better Tolerability = Maximum Efficacy & Improved Trial Outcome Benefit of 20+ Years of Imatinib Clinical Experience “Study-drug discontinuations  Gradual 12-week Titration to max dose (vs 2 Weeks in IMPRES)

  30. Slide 30: IKT's Development and Projected Timelines

    IKT’s Development and Projected Timelines IKT-001 Phase 3 Enrollment Ongoing 26 46 of 180 countries approved, including USA & EU planned sites active 2H 2027 End 2028 ✓ Q4 2025 – Q1 2026 ✓ Mid 2026 Last patient Part A / first patient Part B of Part B enrollment complete of Phase 3 First Phase 3 site

  31. Slide 31: Potential for the 1st Once-Daily Oral Antiproliferative

    Potential for the 1st Once-Daily Oral Antiproliferative Global Pivotal Phase 3 Program with Multiple Clinical Readouts First Half 2027 – Interim Safety Readout Mid 2028 – Part A - PVR Efficacy Data Mid 2029 – Part B – 6MWD Efficacy  Antiproliferatives are the first disease modifying agents  Very H

  32. Slide 32: Thank You

    Thank You

Inhibikase Therapeutics — Investor Presentation (September 2026) on 6ix